卵巢浆液性癌中miR-203和miR-595表达与预后的关系

目的探讨卵巢浆液性癌组织中miR-203、miR-595表达与患者临床病理特征、预后的关系,并分析其对卵巢浆液性癌预后的预测价值。方法收集卵巢浆液性癌的手术组织样本(癌组织和癌旁正常组织),应用RT-PCR技术检测组织样本中miR-203、miR-595的表达;分析癌组织中miR-203、miR-595表达与临床病理特征的关系;Kaplan-Meier生存曲线分析miR-203、miR-595表达与患者预后的关系;Cox回归模型分析卵巢浆液性癌的预后影响因素;受试者工作特征曲线分析miR-203、miR-595表达对卵巢浆液性癌预后的预测价值。结果与癌旁正常组织相比,卵巢浆液性癌组织中miR-203表达增加(P0.05),miR-595表达降低(P0.05)。miR-203表达与淋巴结转移、FIGO分期相关(P均0.05);miR-595表达与组织学分级、淋巴结转移、FIGO分期相关(P均0.05)。Kaplan-Meier生存曲线结果显示,miR-203高表达组、miR-595低表达组患者的预后较差(P均0.05)。Cox回归模型分析结果显示:淋巴结转移、较高FIGO分期、miR-203高表达、miR-595低表达是卵巢浆液性癌预后的独立危险因素(P均0.05)。受试者工作特征曲线结果表明,miR-203、miR-595有较好的预测卵巢浆液性癌预后的价值,CA125、miR-203、miR-595联合检测的灵敏度、特异度分别为0.990、0.867。结论卵巢浆液性癌组织中miR-203高表达,miR-595低表达,且均与较差临床病理特征、不良预后相关;miR-203、miR-595可能是卵巢浆液性癌患者预后预测的潜在指标。     

SF-1、miR-1290、miR-630在子宫内膜癌组织中表达及与TNM分期关系

目的 探讨类固醇生成因子-1(SF-1)、微小RNA-1290(miR-1290)、微小RNA-630(miR-630)在子宫内膜癌组织中表达及与TNM分期关系。方法 选取2015年7月至2021年9月120例子宫内膜癌患者，比较不同组织、不同病理特征、不同随访结局患者组织SF-1、miR-1290、miR-630表达水平，分析组织SF-1、miR-1290、miR-630表达与病理特征关系及其预测随访结局的价值。结果 癌组织SF-1、miR-1290表达高于癌旁组织，miR-630表达低于癌旁组织（t=9.799、12.933、10.915，均为P<0.05）。经相关性分析，组织SF-1、miR-1290表达与分化程度呈负相关（r=-0.759、-0.848，均为P<0.05），与2018FIGO分期、子宫肌层浸润深度、淋巴结转移、远处转移呈正相关（r=0.634、0.688、0.706、0.722;0.825、0.816、0.870、0.853，均为P<0.05）；组织miR-630表达与分化程度呈正相关（r=0.936,P<0.05），与2018FIGO分...     

miR-24在胆管癌组织和细胞系HCCC-9810中的表达

目的探讨microRNA-24(miR-24)在胆管癌患者组织中的表达情况,并分析其表达预后价值及生物学功能。方法收集124例胆管癌患者的癌组织和癌旁组织标本,用实时荧光定量PCR检测miR-24含量,使用χ~2检验对miR-24和胆管癌临床病理学特征的关系进行分析,并通过Kaplan-Meier生存曲线和Cox回归模型评估miR-24在胆管癌中的预后价值。以人胆管癌细胞系HCCC-9810为研究对象,通过转染pEGFP-C1-miR-24融合表达载体,分析miR-24对胆管癌细胞增殖、迁移和侵袭能力的影响。结果 miR-24在胆管癌组织中的表达较癌旁组织上调(P0.05),且与患者淋巴结转移、肿瘤细胞分化及TNM分期显著相关。miR-24高表达的胆管癌患者的整体生存率显著低于低表达患者(P0.001),是胆管癌的独立预后因子(HR=5.518, 95%CI=2.394～12.717,P0.001)。此外,胆管癌细胞中上调的miR-24能够显著地促进癌细胞的增殖、迁移和侵袭的能力。结论胆管癌中表达水平上调的miR-24与患者不良预后显著相关,并参与了胆管癌的进展过程,可能成为胆管癌治疗的新靶点。     

胃癌组织中miR-107、AXIN2的表达及与预后的相关性

目的检测微小RNA-107(microRNA-107, miR-107)和轴抑制蛋白2(axis inhibition protein 2, AXIN2)在胃癌组织中的表达,探讨两者表达的关系及临床意义。方法采用qRT-PCR法检测65例胃癌及正常胃黏膜组织中miR-107和AXIN2 mRNA表达水平;采用免疫组化SP法检测AXIN2蛋白表达水平,分析miR-107、AXIN2与胃癌临床病理特征的关系;Kaplan-Meier法分析胃癌患者术后3年生存期;Cox生存回归分析影响胃癌患者预后的危险因素;Pearson分析胃癌组织中miR-107与AXIN2 mRNA表达水平的相关性。结果胃癌组织中miR-107的表达水平高于正常胃黏膜组织(P0.05),AXIN2 mRNA表达水平及蛋白阳性率均低于正常胃黏膜组织(P0.05);miR-107和AXIN2表达与肿瘤分化程度、淋巴结转移、TNM分期及浸润深度有关(P0.05);miR-107高表达组患者的3年生存率显著低于miR-107低表达组患者,AXIN2高表达组胃癌患者3年生存率显著高于低表达组患者(P0.05);淋巴结转移、TNM分期、miR-107高表达、AXIN2低表达是影响胃癌患者不良预后的独立危险因素(P0.05);胃癌组织中miR-107与AXIN2 mRNA表达呈负相关(r=-0.607,P0.001)。结论胃癌组织中miR-107高表达、AXIN2低表达,且与患者预后有关,可能作为胃癌患者潜在的预后标志物。     

miR-885-5p和RAC1 mRNA在非小细胞肺癌组织中的表达意义及其相关性

目的 检测微小RNA-885-5p(microRNA-885-5p,miR-885-5p)、ras相关C3肉毒菌毒物底物1(the ras-related C3 botulinum toxin substrate 1,RAC1)mRNA在非小细胞肺癌(non-small cell lung cancer,NSCLC)组织中的表达水平,并探讨两者在NSCLC组织中表达的临床意义及其相关性.方法 收集2012年3月至2014年7月期间我院诊治的NSCLC患者的癌组织和其配对的癌旁组织110例,Target Scan7.2在线软件预测miR-885-5p与RAC1的结合位点;采用实时荧光定量PCR(quantitative real-time PCR,qRT-PCR)检测癌组织和癌旁组织中miR-885-5p、RAC1 mRNA的相对表达量,并分析两者在NSCLC癌组织中表达的相关性;分析NSCLC组织中miR-885-5p、RAC1 mRNA的相对表达量与临床病理参数的关系;Kaplan-Meier生存曲线分析miR-885-5p、RAC1 mRNA的相对表达量对NSCLC患者预后的影响;COX多因素分析影响NSCLC患者独立预后的危险因素.结果 miR-885-5p与RAC1基因存在潜在的互补结合位点.与癌旁组织相比,miR-885-5p在NSCLC癌组织中的相对表达量降低(P<0.05),RAC1 mRNA在NSCLC癌组织中的相对表达量增高(P<0.05).miR-885-5p与RAC1 mRNA在NSCLC癌组织中的相对表达量呈负相关(r=-0.540,P<0.001).NSCLC癌组织中miR-885-5p的相对表达量与淋巴结转移和TNM分期相关(P<0.05);RAC1 mRNA的相对表达量与肿瘤的分化程度、淋巴结转移和TNM分期相关(P<0.05).miR-885-5p低表达的NSCLC患者和RAC1mRNA高表达的NSCLC患者预后较差(P<0.05).miR-885-5p低表达、RAC1 mRNA高表达、TNM分期和淋巴结转移是NSCLC患者不良预后的独立危险因素.结论 NSCLC组织中miR-885-5p的表达下调,RAC1 mRNA的表达上调,两者表达呈负相关,且均与预后相关.miR-885-5p、RAC1可能是NSCLC新的预后标志物和治疗靶标.     

miR-23a/b在非小细胞肺癌的表达及临床意义

目的研究miR-23a和miR-23b在非小细胞肺癌中的表达特征,并探讨其临床意义。方法收集157例非小细胞肺癌手术切除标本及50例癌旁组织标本,采用Real time PCR方法检测miR-23a和miR-23b在非小细胞肺癌及其癌旁组织中的表达,分析二者表达的相关性,并探讨其表达与临床病理特征及其预后的关系。结果 miR-23a和miR-23b在非小细胞肺癌组织中的表达水平均高于癌旁肺组织,二者在非小细胞肺癌组织中表达呈正相关(r=0.351,P0.001)。miR-23a和miR-23b联合高表达与淋巴结有无转移(P0.001)、远处转移(P=0.001)及临床分期(P=0.002)相关,而与年龄、性别、组织类型及组织分化程度无显著相关性(P0.05)。KaplanMeier分析显示miR-23a和miR-23b联合高表达组患者生存期显著低于单独高表达组或联合低表达组(P=0.009),Cox风险比例模型分析显示miR-23a和miR-23b联合高表达为非小细胞肺癌患者的危险因素。结论 miR-23a和miR-23b在非小细胞肺癌中异常高表达可能是潜在的肺癌预后分子标志物。     

皮肤恶性黑色素瘤组织miR-205、miR-367表达及其临床意义

目的 探讨皮肤恶性黑色素瘤（CMM）组织中miR-205、miR-367的表达及与临床病理特征和预后的关系。方法选取2013年5月至2019年12月我院收治的85例CMM患者术中切除的肿瘤组织作为CMM组,另选取同期于本院治疗的80例皮肤良性色素痣患者的痣组织标本作为对照组。采用qRT-PCR法检测miR-205、miR-367的表达水平。收集CMM患者的临床病理资料,分析miR-205、miR-367表达与临床病理特征的关系。Kaplan-Meier法绘制患者术后3年的生存曲线,采用Log-rank检验分析患者生存率。COX比例风险回归模型分析预后的影响因素。结果 CMM组患者miR-205表达水平低于对照组（P<0.05）,miR-367表达水平高于对照组（P<0.05）。miR-205低表达组患者溃疡、临床分期高、肿瘤侵袭、KPS评分低、原发灶厚、Clark分级高、淋巴结转移的比例高于miR-205高表达组（P<0.05）,miR-367高表达组患者以上指标比例高于miR-367低表达组（P<0.05）。随访3年,中位时间为28.3个月,失访1例。Kapl...     

乳腺癌组织中miR-199b-5p、miR-597的表达及临床意义

目的检测乳腺癌组织中微小RNA-199b-5p(miR-199b-5p)、微小RNA-597(miR-597)的表达,同时分析miR-199b-5p、miR-597表达与乳腺癌临床病理特征及预后的关系,并分析其早期诊断的价值。方法收集95例乳腺癌组织和癌旁组织,采用实时荧光定量PCR法检测组织中miR-199b-5p、miR-597的相对表达量,分析miR-199b-5p、miR-597表达与乳腺癌临床病理特征的关系;采用Kaplan-Meier生存曲线分析miR-199b-5p、miR-597表达对患者术后5年总生存率的影响,并采用受试者工作特征曲线(receiver operating characteristic,ROC)分析miR-199b-5p和miR-597表达对患者早期诊断的预测价值。结果与癌旁正常组织相比,miR-199b-5p、miR-597在乳腺癌组织中的表达均降低(P均0. 05)。miR-199b-5p低表达与有淋巴结转移和较高TNM分期有关(P均0. 05); miR-597低表达与肿瘤低分化、有淋巴结转移和较高TNM分期有关(P均0. 05)。Kaplan-Meier生存曲线分析结果表明,miR-199b-5p、miR-597低表达患者的总生存率均分别低于miR-199b-5p、miR-597高表达患者(P均0. 05)。此外,miR-199b-5p和miR-597对乳腺癌早期诊断的ROC曲线下面积(area under the cure,AUC)分别为0. 813和0. 721,联合诊断的敏感度和特异度分别为0. 825、0. 813。结论乳腺癌组织中,miR-199b-5p和miR-597表达降低与淋巴结转移、病情恶化、低生存率相关,miR-199b-5p和miR-597有望成为乳腺癌早期诊断和预后预测靶标。     

胃癌组织中CapG蛋白的表达及其与临床病理特征及预后的关系

目的检测巨噬细胞加帽蛋白(gelsolin-like actin-capping protein,CapG)在胃癌及癌旁组织(距离癌组织边缘5 cm)中的表达,探讨CapG蛋白表达与胃癌临床病理参数及预后的关系。方法收集125例胃癌石蜡包埋组织样本及癌旁组织30例。患者均为未行放、化疗的初诊患者。每例组织样本均行CapG免疫组化染色,并设置对照组。通过病理医师评分来确定CapG蛋白的表达量,探讨CapG蛋白表达与胃癌临床病理参数及预后的关系。结果 CapG蛋白在细胞质和细胞核中均表达,呈棕黄色颗粒状。癌旁组织中基本无表达,胃癌组织中的表达显著高于癌旁组织;胃癌组织中CapG蛋白表达与患者性别、年龄、肿瘤大小、肿瘤位置无显著相关(P均0.05),与浸润深度(P=0.044)、淋巴结转移(P=0.026)、远处转移(P=0.001)及AJCC分期(P=0.012)显著相关。Kaplan-Meier生存曲线显示,CapG蛋白高表达组患者的总体预后较低表达组差,且差异具有显著性(P0.001)。Cox回归分析显示,肿瘤位置、淋巴结转移、远处转移、AJCC分期、CapG蛋白表达情况是胃癌患者预后的独立危险因素。结论 CapG蛋白在胃癌组织中高表达,可能与胃癌的发生、发展有关,可作为胃癌预后判断的指标之一,有望成为胃癌治疗的潜在新靶点。     

胃癌中CMTM6和PD-L1的表达及其临床意义

目的 探讨CMTM6和PD-L1在胃癌中的表达及其与临床病理特征、预后的关系。方法 收集103例胃癌患者的临床资料，采用免疫组化MaxVision两步法检测胃癌组织中CMTM6和PD-L1的表达，分析两者表达与临床病理特征的关系。结果 103例胃癌组织中CMTM6高表达70例(68.0%),低表达33例(32.0%);PD-L1高表达66例(64.1%),低表达37例(35.9%)。正常胃黏膜组织中CMTM6高表达39例(37.9%)、低表达64例(62.1%);PD-L1高表达35例(34.0%)、低表达68例(66.0%);两组相比差异有显著性(P<0.001)。CMTM6表达与肿瘤分化程度、浸润深度、脉管浸润、淋巴结转移、远处转移、TNM分期和PD-L1表达相关(P<0.05)。PD-L1表达与患者性别、脉管浸润、神经侵犯和TNM分期相关(P<0.05)。Kaplan-Meier生存分析表明，CMTM6高表达与胃癌患者不良预后相关(P=0.008)。Cox单因素生存分析显示，胃癌患者的预后与肿瘤最大径、浸润深度、脉管浸润、远处转移、淋巴结转移、TNM分期和CMT...     

卵巢癌患者miR-497、miR-125a-5p的表达及与其临床特征和生存率的关系

目的:分析卵巢癌患者癌组织中微小RNA-497(miR-497)和微小RNA-125a-5p(miR-125a-5p)的表达情况及其临床意义。方法:选取2018-06—2019-12在本院手术治疗的96例卵巢癌患者作为研究对象,将手术切除的卵巢癌组织作为试验组,癌旁(>2cm)正常组织为对照组。采用实时荧光定量PCR(qRT-PCR)检测组织中miR-497和miR-125a-5p的表达情况;比较不同临床病理特征卵巢癌患者miR-497和miR-125a-5p表达水平的差异;分析卵巢癌患者三年生存率与miR-497和miR-125a-5p水平的关系;分析影响卵巢癌患者生存率的危险因素。结果:试验组miR-497和miR-125a-5p的表达量均明显低于对照组(P<0.01);与Ⅰ-Ⅱ期卵巢癌患者相比,Ⅲ-Ⅳ期患者miR-497、miR-125a-5p表达水平均较低(P<0.01),与无淋巴结转移患者相比,淋巴结转移者miR-497、miR-125a-5p表达水平均较低(P<0.05);miR-497、miR-125a-5p低表达组生存率均明显低于高表达组(P<0.05);COX回归分析显示miR-497低表达及miR-125a-5p低表达是影响卵巢癌患者生存率的独立危险因素。结论:卵巢癌患者癌组织中miR-497和miR-125a-5p表达下调,其表达水平与卵巢癌患者三年生存率密切相关。     

Expression of miR-32 in human non-small cell lung cancer and its correlation with tumor progression and patient survival

Introduction: miR-32 has recently been found to be implicated in many critical processes in various types of human cancer. However, its clinical significance in human non-small cell lung cancer (NSCLC) has not yet been elucidated. In the present study, we investigated the expression of miR-32 in NSCLC and analyzed its association with clinical features and prognosis of NSCLC patients. Methods: Quantitative real-time PCR (qRT-PCR) was used to measure expression level of miR-32 in lung cancer cell lines, normal bronchial epithelial cells, 90 pairs of tumor samples and adjacent non-tumor tissues. To determine its prognostic value, overall survival was evaluated using the Kaplan-Meier method. Univariate and multivariate analysis were performed using the Cox proportional hazard analysis. Results: The expression of miR-32 was significantly decreased in lung cancer cell lines and NSCLC tissues compared with normal bronchial epithelial cells and adjacent non-tumor tissues (P < 0.05). This reduction of miR-32 was associated with tumor stage and lymph node metastasis (P < 0.05). Moreover, Kaplan-Meier analysis demonstrated that patients with low miR-32 expression had shorter overall survival time than those with high miR-32 expression (P < 0.05). Univariate analysis revealed statistically significant correlations between overall survival and miR-32 level, tumor stage and lymph node metastasis (P < 0.05). Furthermore, miR-32 levels, tumor stage and lymph node metastasis were independently associated with overall survival (P < 0.05). Conclusions: Our results provided the first evidence that down-regulation of miR-32 was correlated with NSCLC progression, and miR-32 might be a potential molecular biomarker for predicting the prognosis of patients.     

MiR-451, a potential prognostic biomarker and tumor suppressor for gastric cancer

Background: The expression of microRNA-451 (miR-451) and its association with clinical pathological factors in GC remain still unclear. The purpose of this study was to investigate if miR-451 is a potential prognostic biomarker and tumor suppressor for gastric cancer. Methods: Real-time quantitative RT-PCR (qRT-PCR) was applied to detect miR-451 expression in GC cell lines and primary tumor and paired non-cancerous tissues. The association of miR-451 expression with clinicopathological factors and prognosis was statistically analyzed. Results: We found that miR-451 showed decreased expression in GC tissues and cell lines, and its down-regulation tended to be positively correlated with lymphatic metastasis, clinical staging and shorter overall survival of patients. In addition, forced expression of miR-451 in BGC-823 and MKN-45 cells did not impact on cell proliferation, but did reduce migration and invasion rates in BGC-823 cells. Conclusion: Our findings indicated that miR-451 may act as a novel prognostic marker and potential therapeutic target in human GC.     

子宫颈癌中miR-153和Survivin的表达及其临床意义

目的探讨miR-153和Survivin在子宫颈癌组织中的表达及其对子宫颈癌的临床意义。方法收集50例子宫颈癌和40例正常子宫颈组织,采用RT-PCR法和免疫组化SP法检测miR-153和Survivin在子宫颈癌和正常子宫颈组织中的表达,分析两者表达与子宫颈癌临床病理特征的关系及对患者预后的意义。结果miR-153在子宫颈癌组织中的相对表达量低于正常子宫颈组织,Survivin在子宫颈癌组织中的相对表达量高于正常子宫颈组织,差异均有统计学意义(t=16.333,t=6.407,P<0.01)。通过散点图及相关性分析,在子宫颈癌组织中miR-153和Survivin相对表达量呈负相关,差异有统计学意义(P<0.01);miR-153、Survivin表达与患者年龄、肿瘤大小、TNM分期均无关(P>0.05),与淋巴结转移明显相关(χ^2=6.455,χ^2=5.937,P<0.05)。通过散点图及相关性分析,淋巴结转移患者的淋巴结受侵数目与miR-153表达量呈负相关,与Survivin表达量呈正相关,差异均有统计学意义(P<0.01)。预后生存分析发现,miR-153高表达患者生存率高于低表达患者,Survivin高表达患者生存率低于低表达患者,差异均有统计学意义(χ^2=19.390,χ^2=27.921,P<0.01)。结论miR-153在子宫颈癌组织中低表达,与Survivin在子宫颈癌组织中表达水平呈负相关,可能与子宫颈癌的增殖、侵袭转移有关。     

MicroRNA-153 expression and prognosis in non-small cell lung cancer

Background: miR-153 has been found to be significantly decreased in non-small cell lung cancer (NSCLC) tissues; however, its clinical significance has not been investigated. Methods: The expression patterns of miR-153 in 137 pairs of human lung cancer tissues and adjacent normal lung tissues were analyzed using qRT-PCR. The relationships between miR-153 expression and clinicopathological parameters were examined by chi-square test. Kaplan-Meier method and the log-rank test were used to determine the difference in overall survival (OS) rates between two groups. Results: The expression of miR-153 was reduced significantly, compared with adjacent normal lung tissues (P<0.05). We observed that the expression level of miR-153 was positively correlated with the clinical stage (P=0.005), lymph node status (P=0.014), distant metastasis (P=0.004), and differentiated degree (P<0.001) in NSCLC patients. According to the Kaplan-Meier survival analysis, the patients with low miR-153 expression exhibited evidently poorer overall survival rates than those with high miR-153 expression (P=0.003). Multivariate analysis showed that the expression of miR-153 was an independent and significant factor associated with poor OS rates (P=0.002). Conclusion: Decreased expression of miR-153 might be a potential unfavorable prognostic factor for patients with NSCLC, and further studies would be needed to prove our findings.     

膀胱尿路上皮癌组织中miR-133b的表达水平与其化疗敏感性的关系分析

目的 探讨膀胱尿路上皮癌组织中miR-133b的表达水平与其化疗敏感性的关系分析.方法 回顾性分析2011年2月至2012年2月于本院确诊为膀胱尿路上皮癌患者65例,根据癌组织中miR-133b表达水平将其分为高表达组(n=25)和低表达组(n=40),采用茎环实时荧光逆转录聚合酶链反应(stem-loop real-time,RT-PCR)检测膀胱尿路上皮癌组织和癌旁正常组织中 mi R-133b的表达水平,随访5年,统计分析所有患者化疗效果、5年存活情况.结果 膀胱尿路上皮癌组织中miR-133b的表达量(U6标准化后的) 低于癌旁正常组织,差异有统计学意义(P<0.05);高表达组患者化疗有效率高于低表达组,差异有统计学意义(P<0.05);所有患者随访0.5~5年,平均随访时间3.86年,最终有45例存活5年以上,高表达组患者5年存活率(88.00%)高于低表达组(57.25%),差异有统计学意义(P<0.05);存活组患者膀胱尿路上皮癌组织中miR-133b水平高于死亡组,差异有统计学意义(P<0.05).结论 与癌旁正常组织比较,膀胱尿路上皮癌组织中miR-133b呈明显低表达,且与术后化疗敏感性、预后有密切关系,有可能作为预测化疗疗效和判断预后的指标之一.     

胃癌组织中microRNA的差异表达

目的 检测胃癌组织和癌旁组织中microRNA (miRNA)的差异表达.方法 收集经病理确诊为胃癌进行外科手术切除的25例患者的胃癌组织及距离胃癌病灶5 cm以上的癌旁组织,选取其中7例标本提取总RNA,应用Illumina miRNA芯片检测胃癌和癌旁组织中差异表达的miRNA.应用定量实时PCR技术验证25例胃癌和癌旁组织标本中差异表达的miRNA,并分析25例患者的临床病理与胃癌组织中miRNA差异表达的关联.结果 Illumina miRNA芯片检测显示,HS-138,HS-153,HS-157在胃癌组织中表达下调,miR-181a,miR-21,miR-21*,miR-27a,miR-584,miR-93在胃癌组织中表达上调.定量实时PCR显示,与癌旁组织比较,胃癌组织中miR-181a表达上调(56.848±135.551比3.950±12.101,P＜0.05),而miR-584在胃癌和癌旁组织中的表达差异无统计学意义(P＞0.05).胃癌组织miR-181a表达与患者胃癌淋巴结转移及年龄有关联(rp=0.462、0.414,P=0.009、0.023),与性别和病理分型无关联(P=0.220、0.106).结论 应用miRNA芯片技术和荧光定量PCR技术发现了胃癌组织中差异表达的miRNA.     

TWIST、HIF-1α、VEGF在胃癌中的表达及意义

目的:探讨TWIST,HIF-1α和VEGF在人胃癌组织中的表达及与临床病理参数、预后的关系。方法:选择120例胃癌标本,应用SP法免疫组化检测TWIST、HIF-1α和VEGF在人胃癌组织中的表达,分析TWIST、HIF-1α和VEGF的表达与患者临床病理参数之间的关系。结果:胃癌组织及正常胃黏膜组织中均可检测到TWIST、HIF-1α和VEGF的表达,但胃癌组织中的表达水平均明显高于正常胃黏膜组织,表达差异有显著性(P<0.05)。TWIST的表达与浸润深度、肿瘤远处转移及淋巴结转移明显相关(P<0.05)。HIF-1α的表达与肿瘤的分化程度、浸润深度及淋巴结转移呈明显相关性(P<0.05)。VEGF的阳性表达与浸润深度、淋巴结转移及TNM分期有关(P<0.05)。TWIST和(或)HIF-1α阳性表达的患者其5年生存率明显低于其阴性表达的患者。结论:胃癌中TWIST、HIF-1α和VEGF的高表达与胃癌的生物学行为及预后密切相关,检测其表达对预测胃癌的转移及判断预后有一定价值。     

MicroRNA-148b is down-regulated in non-small cell lung cancer and associated with poor survival

Background: The aim of this study was to clarify the clinicopathological significance of miRNA-148b (miR-148b) expression in NSCLC, and to explore the correlation between miR-148b level and the prognosis of patients with NSCLC. Methods: 151 patients diagnosed with NSCLC between May 2007 and April 2012 were included in the present study. Real-time RT-PCR method was used to assess the expression levels of miR-148b. The differences between two groups were assessed using Student’s t -test, and the Kaplan-Meier method was used to estimate overall survival. Results: The expression of miR-148b was decreased in tumor tissues compared to corresponding adjacent normal lung tissues (0.37 ± 0.12 vs. 1.00 ± 0.53, P < 0.05). Low miR-148b expression was significantly associated with TNM stage (P = 0.014), lymph node metastasis (P = 0.031), and distant metastasis (P = 0.008). Kaplan-Meier survival analysis showed that patients with low expression of miR-148b had significantly worse overall survival rates compared with those who had cancers with high miR-148b expression (log-rank test P = 0.039). Furthermore, multivariate Cox proportional hazards model analysis showed that miR-148b expression was independently associated with overall survival of patients with NSCLC (HR = 2.357, 95% CI: 1.612-9.212, P = 0.011). Conclusion: our data indicate that decreased expression of miR-148b in NSCLC tissues has prognostic value.     

Up-regulation of miR-335 predicts a favorable prognosis in esophageal squamous cell carcinoma

Introduction: MicroRNAs (miRNAs) are noncoding RNAs that regulate multiple cellular processes during cancer progression. MiR-335 has recently been identified to be involved in tumorigenesis of several cancers such as ovarian cancer and gastric cancer. However, the regulation of miR-335 in esophageal squamous cell carcinoma (ESCC) has not been reported yet. Methods: Expression of miR-335 in tumor and their normal matched tissues was determined by quantitative real-time PCR in 67 ESCC patients and its association with overall survival of patients was analyzed by statistical analysis. Results: The expression level of miR-335 was reduced in malignant tissue samples in comparison to normal matched tissue (P < 0.05). It was also proved that miR-335 expression was associated with ESCC histological grade, lymph node metastasis, tumor stage and clinical stage (P < 0.05). In addition, the Kaplan-Meier survival curves revealed that low miR-335 expression was associated with poor prognosis in ESCC patients. Multivariate analysis showed that miR-335 expression was an independent prognostic marker of overall survival of ESCC patients. Conclusions: The study proves for the first time that miR-335 is down regulated in a majority of ESCC patients. Our results indicate that miR-335 expression is an independent prognostic factor for patients with esophageal cancer, which might be a potential valuable biomarker for ESCC.